Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application

0 PSYCHOLOGY, CLINICAL
Diana Bowser , Robert Bohler , Margot T. Davis , Dominic Hodgkin , Constance Horgan
{"title":"Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application","authors":"Diana Bowser ,&nbsp;Robert Bohler ,&nbsp;Margot T. Davis ,&nbsp;Dominic Hodgkin ,&nbsp;Constance Horgan","doi":"10.1016/j.josat.2024.209441","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The national opioid crisis continues to intensify, despite the fact that opioid use disorder (OUD) is treatable and opioid overdose deaths are preventable through first-line treatment with medications for opioid use disorder (MOUD). This study identifies and categorizes payment-related barriers that impact MOUD access and retention from both the provider and patient perspectives and provides insight into how these barriers can be addressed.</p></div><div><h3>Methods</h3><p>We performed a critical review of the literature (peer-reviewed studies and relevant documents from the gray literature) to identify payment-related access and retention barriers to MOUD. We used the results of this review to develop an analytic framework to understand how payment impacts MOUD access and retention for both providers and patients. In addition, we reviewed action plans developed by Massachusetts communities that participated in the Healing Communities Study (HCS) to analyze which payment-related barriers were addressed through the study.</p></div><div><h3>Results</h3><p>We identified 18 payment-related barriers that patients or providers face when initiating or continuing MOUD with either methadone or buprenorphine in Opioid Treatment Programs (OTP) and non-OTP settings. Patient-related barriers mainly relate to health insurance coverage or the design of health plans (e.g., cost sharing, covered benefits) resulting in direct (medical and non-medical) and indirect costs that can affect both access and retention, especially as they relate to services provided in OTPs. Provider-related barriers include low reimbursement and administrative burden and are most likely to impact access to MOUD. Evidence-based strategies to expand MOUD as part of the HCS in Massachusetts targeted about half of the patient and provider payment-related barriers identified.</p></div><div><h3>Conclusion</h3><p>Patients and providers face an array of payment-related barriers that impact access to and retention on MOUD, most of which relate to inadequate health insurance coverage, features of health plans, and key federal and state policies. As new regulatory policies are enacted that expand access to MOUD, such as greater flexibility in OTPs and MOUD delivered via telehealth, it will be important to align these delivery changes with payment reform involving payers, providers, and policymakers.</p></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294987592400153X/pdfft?md5=27a843c3a37f30cb20a7d0178836a245&pid=1-s2.0-S294987592400153X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of substance use and addiction treatment","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S294987592400153X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The national opioid crisis continues to intensify, despite the fact that opioid use disorder (OUD) is treatable and opioid overdose deaths are preventable through first-line treatment with medications for opioid use disorder (MOUD). This study identifies and categorizes payment-related barriers that impact MOUD access and retention from both the provider and patient perspectives and provides insight into how these barriers can be addressed.

Methods

We performed a critical review of the literature (peer-reviewed studies and relevant documents from the gray literature) to identify payment-related access and retention barriers to MOUD. We used the results of this review to develop an analytic framework to understand how payment impacts MOUD access and retention for both providers and patients. In addition, we reviewed action plans developed by Massachusetts communities that participated in the Healing Communities Study (HCS) to analyze which payment-related barriers were addressed through the study.

Results

We identified 18 payment-related barriers that patients or providers face when initiating or continuing MOUD with either methadone or buprenorphine in Opioid Treatment Programs (OTP) and non-OTP settings. Patient-related barriers mainly relate to health insurance coverage or the design of health plans (e.g., cost sharing, covered benefits) resulting in direct (medical and non-medical) and indirect costs that can affect both access and retention, especially as they relate to services provided in OTPs. Provider-related barriers include low reimbursement and administrative burden and are most likely to impact access to MOUD. Evidence-based strategies to expand MOUD as part of the HCS in Massachusetts targeted about half of the patient and provider payment-related barriers identified.

Conclusion

Patients and providers face an array of payment-related barriers that impact access to and retention on MOUD, most of which relate to inadequate health insurance coverage, features of health plans, and key federal and state policies. As new regulatory policies are enacted that expand access to MOUD, such as greater flexibility in OTPs and MOUD delivered via telehealth, it will be important to align these delivery changes with payment reform involving payers, providers, and policymakers.

与支付有关的阿片类药物使用障碍:文献综述与现实应用。
背景:尽管阿片类药物使用失调症(OUD)是可以治疗的,而且通过阿片类药物使用失调症(MOUD)的一线药物治疗可以预防阿片类药物过量死亡,但全国阿片类药物危机仍在加剧。本研究从医疗服务提供者和患者的角度出发,对影响阿片类药物使用障碍(MOUD)治疗机会和保留率的支付相关障碍进行了识别和分类,并就如何解决这些障碍提出了见解:我们对文献(同行评议研究和灰色文献中的相关文件)进行了批判性综述,以确定与支付相关的牟取和保留牟利障碍。我们利用综述结果制定了一个分析框架,以了解支付如何影响医疗服务提供者和患者获取和保留 MOUD。此外,我们还审查了参与 "愈合社区研究"(HCS)的马萨诸塞州社区制定的行动计划,以分析该研究解决了哪些与支付相关的障碍:我们确定了患者或医疗服务提供者在阿片类药物治疗计划(OTP)和非 OTP 环境下开始或继续使用美沙酮或丁丙诺啡进行 MOUD 时所面临的 18 个与支付相关的障碍。与患者相关的障碍主要涉及医疗保险范围或医疗计划的设计(如费用分担、承保福利),从而导致直接(医疗和非医疗)和间接成本,这可能会影响患者获得和继续治疗,尤其是与 OTPs 提供的服务相关的成本。与提供者相关的障碍包括报销额度低和行政负担重,最有可能影响 MOUD 的获取。在马萨诸塞州,作为保健服务的一部分,扩大 MOUD 的循证策略针对的是约一半的患者和医疗服务提供者与支付相关的障碍:患者和医疗服务提供者面临着一系列与支付相关的障碍,这些障碍影响了他们获得和保留 MOUD 的机会,其中大部分与医疗保险覆盖面不足、医疗计划的特点以及主要的联邦和州政策有关。随着新的监管政策的颁布,MOUD 的使用范围也在不断扩大,如开放式门诊和通过远程医疗提供的 MOUD 具有更大的灵活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of substance use and addiction treatment
Journal of substance use and addiction treatment Biological Psychiatry, Neuroscience (General), Psychiatry and Mental Health, Psychology (General)
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信